Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2014


#198008

115pages

Global Markets Direct

$ 2000

In Stock

 

This report provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects.

 

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

  • The report provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Hematopoietic Stem Cell Transplantation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

 

Reasons to buy

 

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hematopoietic Stem Cell Transplantation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents


Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hematopoietic Stem Cell Transplantation Overview 9
Therapeutics Development 10
Pipeline Products for Hematopoietic Stem Cell Transplantation - Overview 10
Pipeline Products for Hematopoietic Stem Cell Transplantation - Comparative Analysis 11
Hematopoietic Stem Cell Transplantation - Therapeutics under Development by Companies 12
Hematopoietic Stem Cell Transplantation - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Hematopoietic Stem Cell Transplantation - Products under Development by Companies 18
Hematopoietic Stem Cell Transplantation - Companies Involved in Therapeutics Development 20
Hospira, Inc. 20
Athersys, Inc. 21
GlaxoSmithKline plc 22
BioLineRx, Ltd. 23
Novartis AG 24
Celldex Therapeutics, Inc. 25
Antisense Therapeutics Limited 26
Actinium Pharmaceuticals, Inc. 27
Pharmalink AB 28
Recoly N.V. 29
Polyphor Ltd. 30
Kiadis Pharma B.V. 31
Bellicum Pharmaceuticals, Inc. 32
TaiGen Biotechnology Co., Ltd. 33
TikoMed AB 34
Tarix Pharmaceuticals LTD. 35
Hematopoietic Stem Cell Transplantation - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 40
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 48
Iomab-B - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ronacaleret hydrochloride - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
busulfan liposomal IR - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ATIR - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
POL-6326 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
TXA-127 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
burixafor - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BL-8040 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
HSC-835 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
BPX-501 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
TM-400 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ASC-101 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MultiStem - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CDX-301 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ATL-1102 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
filgrastim - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
NecLip-G-CSF - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
BL-8040 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
POL-5551 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Actimab-B - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Cordsafe - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Hematopoietic Stem Cell Transplantation - Recent Pipeline Updates 81
Hematopoietic Stem Cell Transplantation - Dormant Projects 103
Hematopoietic Stem Cell Transplantation - Discontinued Products 104
Hematopoietic Stem Cell Transplantation - Product Development Milestones 105
Featured News & Press Releases 105
Jan 29, 2014: Actinium Engages Goodwin Biotechnology to Supply Iomab-B for Its Phase 3 Clinical Study 105
Jan 22, 2014: ATL1102 for Stem Cell Mobilisation Trial Approval 105
Jan 09, 2014: Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference 106
Dec 19, 2013: Actinium Completes Technology Transfer for Manufacturing of Its Lead Drug Candidate Iomab-B 106
Dec 18, 2013: Targazym Reports Interim Phase I/IIa Trial Results for TZ101 107
Dec 10, 2013: Celldex's CDX-301 in Combination with Mozobil Increases Hematopoietic Stem Cell Mobilization and Results in Improved Transplantation of Mobilized Cells in Preclinical Studies; Results Presented at ASH 2013 108
Nov 29, 2013: ATL1102 for Stem Cell Mobilisation: Application to Conduct Human Proof of Concept Clinical Trial Submitted 109
Oct 03, 2013: Actinium Pharmaceuticals Announces Upcoming Webinar To Discuss Iomab-B 110
Sep 11, 2013: Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR and Study Meets Primary Objective 110
Sep 11, 2013: Chimerix Presents Brincidofovir Adenovirus Phase 2 Results 111
 

Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 115
Disclaimer 115


Number of Products under Development for Hematopoietic Stem Cell Transplantation, H1 2014 10
Number of Products under Development for Hematopoietic Stem Cell Transplantation - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Development by Companies, H1 2014 (Contd..1) 19
Hematopoietic Stem Cell Transplantation - Pipeline by Hospira, Inc., H1 2014 20
Hematopoietic Stem Cell Transplantation - Pipeline by Athersys, Inc., H1 2014 21
Hematopoietic Stem Cell Transplantation - Pipeline by GlaxoSmithKline plc, H1 2014 22
Hematopoietic Stem Cell Transplantation - Pipeline by BioLineRx, Ltd., H1 2014 23
Hematopoietic Stem Cell Transplantation - Pipeline by Novartis AG, H1 2014 24
Hematopoietic Stem Cell Transplantation - Pipeline by Celldex Therapeutics, Inc., H1 2014 25
Hematopoietic Stem Cell Transplantation - Pipeline by Antisense Therapeutics Limited, H1 2014 26
Hematopoietic Stem Cell Transplantation - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 27
Hematopoietic Stem Cell Transplantation - Pipeline by Pharmalink AB, H1 2014 28
Hematopoietic Stem Cell Transplantation - Pipeline by Recoly N.V., H1 2014 29
Hematopoietic Stem Cell Transplantation - Pipeline by Polyphor Ltd., H1 2014 30
Hematopoietic Stem Cell Transplantation - Pipeline by Kiadis Pharma B.V., H1 2014 31
Hematopoietic Stem Cell Transplantation - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014 32
Hematopoietic Stem Cell Transplantation - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2014 33
Hematopoietic Stem Cell Transplantation - Pipeline by TikoMed AB., H1 2014 34
Hematopoietic Stem Cell Transplantation - Pipeline by Tarix Pharmaceuticals LTD., H1 2014 35
Assessment by Monotherapy Products, H1 2014 36
Number of Products by Stage and Target, H1 2014 39
Number of Products by Stage and Mechanism of Action, H1 2014 42
Number of Products by Stage and Route of Administration, H1 2014 44
Number of Products by Stage and Molecule Type, H1 2014 47
Hematopoietic Stem Cell Transplantation Therapeutics - Recent Pipeline Updates, H1 2014 81
Hematopoietic Stem Cell Transplantation - Dormant Projects, H1 2014 103
Hematopoietic Stem Cell Transplantation - Discontinued Products, H1 2014 104


Number of Products under Development for Hematopoietic Stem Cell Transplantation, H1 2014 10
Number of Products under Development for Hematopoietic Stem Cell Transplantation - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 16
Assessment by Monotherapy Products, H1 2014 36
Number of Products by Top 10 Target, H1 2014 37
Number of Products by Stage and Top 10 Target, H1 2014 38
Number of Products by Top 10 Mechanism of Action, H1 2014 40
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 41
Number of Products by Top 10 Route of Administration, H1 2014 43
Number of Products by Stage and Top 10 Route of Administration, H1 2014 44
Number of Products by Top 10 Molecule Type, H1 2014 45
Number of Products by Stage and Top 10 Molecule Type, H1 2014 46